Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
about
Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment.Solifenacin significantly improves all symptoms of overactive bladder syndrome.Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.Medical management of overactive bladderMuscarinic receptors in the bladder: from basic research to therapeutics.Incontinence medication response relates to the female urinary microbiota.The emergence of new drugs for overactive bladder.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.A review of solifenacin in the treatment of urinary incontinence.Pharmacologic management of overactive bladder.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Solifenacin at 3 years: a review of efficacy and safety.Social, economic, and health utility considerations in the treatment of overactive bladder.New once-daily formulation for trospium in overactive bladder.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Solifenacin: pharmacology and clinical efficacy.Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.Persistence with mirabegron therapy for overactive bladder: A real life experience.Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey.Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.Clinical guidelines for overactive bladder.Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.Effectiveness of Solifenacin for Managing of Bladder Spasms in Patients With Urethroplasty.Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome.Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
P2860
Q30410914-2490E3A1-9729-4F29-B32B-494F7B85F32CQ30445725-C98B9ED3-B434-4D6E-90B7-507DE3D242AFQ31013378-B638D3E8-386B-453E-87B6-14A77E40258BQ33560320-C0157410-9559-412F-8F50-BC66DEBCA95EQ33716568-38035D91-C0A3-4009-8726-F5AA2AA06240Q34124065-106A5406-B384-443A-BF34-481D4DBF513EQ34564708-6211C844-30D0-4659-908F-7CBE21C575C1Q35794040-4598B72D-6905-422F-91F4-4A32D49407F7Q36407417-125402E1-5981-4A1D-BF27-3D3A4F40249FQ36428471-9A7F4476-D40A-4054-BD85-3E3172F33544Q36655193-3EB183CC-CB71-4E77-AD5B-83CA5C4A6C88Q36822864-7ADBEC2E-1FB2-4225-953A-09AA80A194A0Q37017434-0CF95E89-B771-4A43-8411-8E78C5904952Q37187453-3E0B8624-7B0C-49DC-9F1E-18A834AB7E07Q37226401-7B08129C-F1FC-43B9-A5DA-60B71A20BBA3Q37283547-C6665EE2-2158-4634-8B4B-181B15E81929Q37789419-A1A29BF6-531B-402A-A631-CDCB2B1077A1Q37864717-E64A4279-171A-4961-ACB9-C40E9DB63FB9Q37914849-B7857472-1D7C-4A1A-8450-1EF92EEF5B02Q38177369-E3D9ED74-6BD0-4262-816C-E82AF7437496Q38634816-72682AD2-857B-4A83-80A8-6B30931C38B3Q39268095-6C365534-0C3D-4490-A42A-DF7A6BE40B8BQ39351514-363184AC-C379-4EEA-8041-1D7D17311B6EQ40161984-7CD8DE28-F066-4475-8C5C-5BACE85F779CQ40210488-AC3EFB65-4BF6-4F53-B8DC-8C72784B9098Q40216123-17D6ACDB-C3D2-4BAF-ABEA-FD12D5106ABFQ42626930-E11C0A07-96E4-4140-B23D-5C81FCDAF306Q42671934-DEFD527A-3FB5-47BC-9BC1-B5ACB2B4BB8FQ43263705-D0690286-EDB0-4A24-A379-55EFCF23B137Q46113025-E9335B19-ECA1-4169-8F0C-E5A57AEF3589Q46116817-1DF3747F-D06D-4DA4-AE9C-46BCB8FA5068Q46351979-29BF0F62-C836-433E-9F68-917EA5E2D428Q46398901-632D23D2-1E77-451F-8D78-83BC0E100107Q47152244-02A51210-D490-4A90-81D2-6CE1F58CC1DCQ47873674-1A0A047F-005C-4F20-A6E3-43277003887DQ48030253-BDC6C896-1B14-41CB-BB56-443920B29692Q53149368-44F5D153-B56D-4B62-8D97-FF9878847C5EQ53236412-0544FF9B-903E-45A0-823E-624A9546524B
P2860
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Long-term open-label solifenac ...... h overactive bladder syndrome.
@en
Long-term open-label solifenac ...... h overactive bladder syndrome.
@nl
type
label
Long-term open-label solifenac ...... h overactive bladder syndrome.
@en
Long-term open-label solifenac ...... h overactive bladder syndrome.
@nl
prefLabel
Long-term open-label solifenac ...... h overactive bladder syndrome.
@en
Long-term open-label solifenac ...... h overactive bladder syndrome.
@nl
P2093
P1433
P1476
Long-term open-label solifenac ...... h overactive bladder syndrome.
@en
P2093
A M Ridder
Solifenacin Study Group
P304
P356
10.1016/J.EURURO.2004.11.004
P407
P577
2005-01-05T00:00:00Z